The Phase 1b/2a clinical trial found that AB-2004 lowered blood and urinary levels of gut-derived metabolites and improved irritability and anxiety in adolescents with Autism Spectrum Disorder. The study's results support the potential of AB-2004 as a novel therapeutic approach for treating co-occurring conditions associated with ASD.
ALS Ventures has closed its first round of investments with a $59M commitment, targeting novel therapeutics in preclinical development. The firm aims to accelerate R&D from discovery stage to late preclinical development.
Novotech was recognized for its expertise in Asia-Pacific and commitment to meeting customer needs. The CRO won awards in key categories including Compatibility, Capabilities, Quality, and Reliability.
The Asia-Pacific region has launched expedited review processes for COVID-19 treatment and vaccine trials, with South Korea offering approval in under 9 days. Novotech is a leading contract research organization (CRO) in the region, supporting vital research with its fast-track services.
Novotech Research reveals that the top 10 biotech sites in Australia are open for clinical trial activity. The country's favorable environment is supporting clinical research during the global COVID-19 crisis, with many sites modifying their practices to ensure continuity of operations.
Researchers at the Australian Centre for Digestive Diseases have successfully treated Crohn's disease in patients, achieving prolonged remission of 3-23 years. The treatment uses a combination of specific antibiotics and Faecal Microbiota Transfer (FMT) to repopulate the gut with healthy bacteria.